Biologic Drug Product Outsourcing Drivers by Company Size
Source: ISR Reports
In Q3 2021, ISR surveyed 136 sponsors who outsource biologic drug product manufacturing to learn more about their primary reason for outsourcing. The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (71%) while sponsors from non-large pharma use CMOs for all manufacturing needs (66%). To learn more, follow the link to the Biologic Drug Product CDMO Benchmarking report preview.
VIEW THE INFOGRAPHIC!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more